{
  "source": "PA-Notification-Haegarda.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1225-9\nProgram Prior Authorization/Notification\nMedication Haegarda® (C1 esterase inhibitor Subcutaneous, human)\nP&T Approval Date 8/2017, 7/2018, 7/2019, 7/2020, 7/2021, 7/2022, 7/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nHaegarda is a plasma-derived concentrate of C1 esterase inhibitor (human) (C1-INH) indicated\nfor routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of\nage and older.1\n2. Coverage Criteriaa:\nA. Haegarda will be approved based on all of the following criteria:\n1. Diagnosis of hereditary angioedema (HAE)\n-AND-\n2. For prophylaxis against HAE attacks\n-AND-\n3. Not used in combination with other products indicated for prophylaxis against HAE attacks\n(e.g., Cinryze, Takhzyro, Orladeyo)\nAuthorization of therapy will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Haegarda [package insert]. Kankakee, IL: CSL Behring LLC.; January 2022.\n© 2025 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification – Haegarda (C1 esterase inhibitor\nsubcutaneous, human)\nChange Control\n8/2017 New program.\n7/2018 Annual review. No changes to the coverage criteria. Updated\nreferences.\n7/2019 Annual review. No changes to the program.\n7/2020 Annual review. No changes to coverage criteria. Updated background.\n7/2021 Annual review. Updated combination use criteria to include all\nprophylaxis a",
    "Annual review. No changes to the program.\n7/2020 Annual review. No changes to coverage criteria. Updated background.\n7/2021 Annual review. Updated combination use criteria to include all\nprophylaxis agents. Updated references and background.\n7/2022 Annual review with no changes to coverage criteria. Added state\nmandate footnote. Updated reference.\n7/2023 Annual review. Revised wording of criteria without change to clinical\nintent.\n3/2024 Annual review. No changes to coverage criteria.\n3/2025 Annual review. No changes to coverage criteria.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}